drugset / Trial / NCT02933320
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Phase 1/2
Completed
14 enrolled
Cancer Research UK
BioInvent International AB · collabBloodwise · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody.
Timeline
- Start
- 2016-10-27
- Primary completion
- 2020-03-19
- Completion
- 2020-03-19